# Financial Times

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/financial-times
Canonical HTML page: https://getbiobrief.com/entity/financial-times

## Recent coverage (2 stories)

### AstraZeneca and BMS in Talks for £300bn Biotech Consolidation Play
2026-08-03 09:56:53 · Sentiment: Neutral · Impact: 9/10 · Sources: 4

The potential merger could dramatically reshape oncology and cardiovascular R&D pipelines, triggering a wave of consolidation among biotech firms seeking scale to compete with the new behemoth.
Full story: https://getbiobrief.com/story/astrazeneca-bms-biotech-merger-300bn

### AstraZeneca, BMS Eye $400B Union to Build Cancer Powerhouse
2026-08-02 23:37:29 · Sentiment: Neutral · Impact: 9/10 · Sources: 2

The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Full story: https://getbiobrief.com/story/astrazeneca-bms-oncology-pipeline-merger

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.